TARSUS PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
TARSUS PHARMACEUTICALS, INC. (TARS) reported Net Income (Loss) Available to Common Stockholders, Basic of -$22.51 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-11-09
- TARSUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$22.51M.
- TARSUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$5.74M, a 191.17% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$20.24M, a 296.75% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$15.70M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month |
|---|---|---|---|
| 2022-09-30 | -$22.51M 10-Q · filed 2022-11-09 | -$28.25M derived: sum of 2 quarters · filed 2022-11-09 | -$48.49M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$5.74M 10-Q · filed 2022-08-11 | -$25.98M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$20.24M 10-Q · filed 2022-05-11 | ||
| 2021-09-30 | -$15.70M 10-Q · filed 2022-11-09 | -$9.40M derived: sum of 2 quarters · filed 2022-11-09 | $1.02M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $6.30M 10-Q · filed 2022-08-11 | $16.59M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $10.29M 10-Q · filed 2022-05-11 | ||
| 2020-09-30 | -$10.14M 10-Q · filed 2021-11-10 | -$13.39M derived: sum of 2 quarters · filed 2021-11-10 | -$15.34M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$3.25M 10-Q · filed 2021-08-05 | -$5.21M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | -$1.96M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |